FDA Approves Abbott's FreeStyle Libre Glucose Monitoring System
Abbott Laboratories has received U.S. Food and Drug Administration (FDA) approval for its FreeStyle Libre Flash Glucose Monitoring System, offering a new option for diabetes management.
The U.S. Food and Drug Administration (FDA) has approved Abbott Laboratories' FreeStyle Libre Flash Glucose Monitoring System, providing a new choice for diabetes management in the United States. The approval applies to the roughly 30 million Americans living with diabetes.
The FreeStyle Libre system replaces the need for routine fingersticks and fingerstick calibrations associated with traditional glucose monitoring. Instead, it uses a small sensor applied to the back of the upper arm. This sensor measures glucose levels continuously for up to 10 days and transmits the data wirelessly to a handheld reader.
The reader displays real-time glucose readings, an 8-hour historical trend, and a trend arrow indicating the direction of glucose levels. This data aims to help users make informed decisions about their diet, exercise, and insulin dosage. Studies suggest users experience less time spent in hypoglycemia (low blood sugar) compared to those using traditional monitoring methods.
The system's ease of use is highlighted by its ability to read glucose levels through clothing and its compact design. Globally, over 400,000 people are reportedly using the FreeStyle Libre system, which Abbott states has been clinically proven for accuracy and stability.